Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

(2021) Martin J van den Bent et al.   LANCET ONCOLOGY

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

(2021) David N Louis et al.   NEURO-ONCOLOGY

Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma

(2020) William G Breen et al.   NEURO-ONCOLOGY

Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter-methylated malignant astrocytoma

(2020) Antje Wick et al.   NEURO-ONCOLOGY

A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)

(2020) Carmen Balana et al.   NEURO-ONCOLOGY

Histone H3K27M Mutation Overrides Histological Grading in Pediatric Gliomas

(2020) Amal Mosaab et al.   Scientific Reports

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma

(2020) David A. Reardon et al.   JAMA Oncology

Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma

(2020) Erica H. Bell et al.   JOURNAL OF CLINICAL ONCOLOGY

CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design.

(2020) Kurt A Jaeckle et al.   NEURO-ONCOLOGY

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

(2019) Ulrich Herrlinger et al.   LANCET

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016

(2019) Quinn T Ostrom et al.   NEURO-ONCOLOGY

Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study)

(2019) Kihwan Hwang et al.   Cancer Research and Treatment

Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial

(2018) H -G Wirsching et al.   ANNALS OF ONCOLOGY

Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology

(2018) Supriya G. Mohile et al.   JOURNAL OF CLINICAL ONCOLOGY

Hypofractionated accelerated radiotherapy (HART) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: a phase II randomized trial (HART-GBM trial)

(2018) Supriya Mallick et al.   JOURNAL OF NEURO-ONCOLOGY

NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patients

(2018) Arif N. Ali et al.   JOURNAL OF NEURO-ONCOLOGY

Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With BRAF -Mutated High-Grade Glioma

(2018) Tanner M. Johanns et al.   Journal of the National Comprehensive Cancer Network

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma

(2018) Linda M. Liau et al.   Journal of Translational Medicine

cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

(2018) Daniel J. Brat et al.   ACTA NEUROPATHOLOGICA

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

(2018) Martin J van den Bent et al.   LANCET ONCOLOGY

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma

(2018) Alba A. Brandes et al.   ONCOLOGIST

Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial

(2018) Giuseppe Lombardi et al.   LANCET ONCOLOGY

A randomized, double-blind, phase III trial of personalized peptide vaccination for recurrent glioblastoma

(2018) Yoshitaka Narita et al.   NEURO-ONCOLOGY

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

(2017) Roger Stupp et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline

(2017) Timothy Gilligan et al.   JOURNAL OF CLINICAL ONCOLOGY

Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update

(2017) Betty R. Ferrell et al.   JOURNAL OF CLINICAL ONCOLOGY

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

(2017) Martin J van den Bent et al.   LANCET

Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

(2017) Michael Weller et al.   LANCET ONCOLOGY

Cost-effectiveness of radiation and chemotherapy for high-risk low-grade glioma

(2017) Yushen Qian et al.   NEURO-ONCOLOGY

Reply to letter on results of NRG Oncology RTOG 9813

(2017) Susan M. Chang et al.   NEURO-ONCOLOGY

A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913

(2017) Prakash Chinnaiyan et al.   NEURO-ONCOLOGY

Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma

(2017) James R. Perry et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lomustine and Bevacizumab in Progressive Glioblastoma

(2017) Wolfgang Wick et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

(2017) Alexander Drilon et al.   Cancer Discovery

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

(2016) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

(2016) Ulrich Herrlinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial

(2016) Carmen Balana et al.   JOURNAL OF NEURO-ONCOLOGY

NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma

(2016) Mark R. Gilbert et al.   JOURNAL OF NEURO-ONCOLOGY

A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma

(2016) Shiao-Pei Weathers et al.   JOURNAL OF NEURO-ONCOLOGY

Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

(2016) Brigitta G Baumert et al.   LANCET ONCOLOGY

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma

(2016) Jan C. Buckner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations

(2015) David A. Solomon et al.   BRAIN PATHOLOGY

Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients? A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial

(2015) Liang-Fu Zhou et al.   CHINESE MEDICAL JOURNAL

A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma

(2015) Manfred Westphal et al.   EUROPEAN JOURNAL OF CANCER

International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme

(2015) Wilson Roa et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options

(2015) Lowell E. Schnipper et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma

(2015) Kathryn M. Field et al.   NEURO-ONCOLOGY

Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial

(2015) Hendrikus J. Dubbink et al.   NEURO-ONCOLOGY

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

(2015) L. Burt Nabors et al.   NEURO-ONCOLOGY

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors

(2015) Jeanette E. Eckel-Passow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas

(2015)   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study

(2014) Kenneth F. Hofland et al.   ACTA ONCOLOGICA

Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared with temozolomide-chemoradiation for unresectable glioblastoma: final results of the TEMAVIR study from ANOCEF†

(2014) B. Chauffert et al.   ANNALS OF ONCOLOGY

A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma

(2014) W. Wick et al.   CLINICAL CANCER RESEARCH

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

(2014) Walter Taal et al.   LANCET ONCOLOGY

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

(2014) Roger Stupp et al.   LANCET ONCOLOGY

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

(2014) Mark R. Gilbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial

(2013) Maria Teresa Solomón et al.   BMC CANCER

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

(2013) Mark R. Gilbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia

(2013) Stacie B. Dusetzina et al.   JOURNAL OF CLINICAL ONCOLOGY

The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States

(2013) A. Messali et al.   NEURO-ONCOLOGY

Enrollment of Patients With Lung and Colorectal Cancers Onto Clinical Trials

(2013) Mona N. Fouad et al.   Journal of Oncology Practice

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

(2012) Roger Stupp et al.   EUROPEAN JOURNAL OF CANCER

Randomized Trial of Radiation Therapy Plus Procarbazine, Lomustine, and Vincristine Chemotherapy for Supratentorial Adult Low-Grade Glioma: Initial Results of RTOG 9802

(2012) Edward G. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

(2012) Annika Malmström et al.   LANCET ONCOLOGY

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

(2012) Wolfgang Wick et al.   LANCET ONCOLOGY

Building better guidelines with BRIDGE-Wiz: development and evaluation of a software assistant to promote clarity, transparency, and implementability

(2011) Richard N Shiffman et al.   JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION

Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions

(2011) Sonya Blesser Streeter et al.   Journal of Oncology Practice

Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma

(2010) Michael Brada et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of Concurrent Topotecan and Radiation on 6-Month Progression-Free Survival in the Primary Treatment of Glioblastoma Multiforme

(2009) Gerhard G. Grabenbauer et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

(2009) Jennifer L. Clarke et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology Guidance Statement: The Cost of Cancer Care

(2009) Neal J. Meropol et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

(2009) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

IDH1andIDH2Mutations in Gliomas

(2009) Hai Yan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

(2008) David A. Reardon et al.   JOURNAL OF CLINICAL ONCOLOGY

An Integrated Genomic Analysis of Human Glioblastoma Multiforme

(2008) D. W. Parsons et al.   SCIENCE

Randomized Study of Postoperative Radiotherapy and Simultaneous Temozolomide without Adjuvant Chemotherapy for Glioblastoma

(2008) Martin Kocher et al.   STRAHLENTHERAPIE UND ONKOLOGIE